Immunomodulating agents and hepatic drug-metabolizing enzymes
Immunomodulating agents are increasingly used in clinical practice to alter the course of various malignancies, autoimmune diseases, or immunodeficiencies. Experimental data obtained in laboratory animals suggest that nearly all agents available today are likely to inhibit hepatic drug-metabolizing enzymes. Although further investigation is warranted, a direct stimulation of the reticuloendothelial system is likely to play a key role. Potentially severe drug interactions are the main clinical consequences to be considered, particularly in the field of cancer chemoimmunotherapy and vaccination. Besides immunomodulating agents, drugs with the toxic potential for immunoenhancement may also be considered in that respect.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1985 |
|---|---|
| Erschienen: |
1985 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 16(1985), 1-2 vom: 15., Seite 175-84 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Descotes, J [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.01.1986 Date Revised 17.11.2004 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM03886567X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM03886567X | ||
| 003 | DE-627 | ||
| 005 | 20231221143926.0 | ||
| 007 | tu | ||
| 008 | 231221s1985 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0130.xml |
| 035 | |a (DE-627)NLM03886567X | ||
| 035 | |a (NLM)3905318 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Descotes, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunomodulating agents and hepatic drug-metabolizing enzymes |
| 264 | 1 | |c 1985 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.1986 | ||
| 500 | |a Date Revised 17.11.2004 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Immunomodulating agents are increasingly used in clinical practice to alter the course of various malignancies, autoimmune diseases, or immunodeficiencies. Experimental data obtained in laboratory animals suggest that nearly all agents available today are likely to inhibit hepatic drug-metabolizing enzymes. Although further investigation is warranted, a direct stimulation of the reticuloendothelial system is likely to play a key role. Potentially severe drug interactions are the main clinical consequences to be considered, particularly in the field of cancer chemoimmunotherapy and vaccination. Besides immunomodulating agents, drugs with the toxic potential for immunoenhancement may also be considered in that respect | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d 1973 |g 16(1985), 1-2 vom: 15., Seite 175-84 |w (DE-627)NLM000049530 |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:1985 |g number:1-2 |g day:15 |g pages:175-84 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 1985 |e 1-2 |b 15 |h 175-84 | ||